Sg3 Management, LLC Gilead Sciences, Inc. Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $317,460 - $357,555	-5,500 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $1.27 Million - $1.6 Million	-22,000 Reduced 80.0%	5,500 $327,000
Q4 2021 Feb 15, 2022	BUY	$64.88 - $73.64 $1.36 Million - $1.55 Million	21,000 Added 323.08%	27,500 $2 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $545,842 - $596,410	-8,600 Reduced 56.95%	6,500 $448,000
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $246,000 - $280,686	4,100 Added 37.27%	15,100 $976,000
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $453,200 - $516,400	8,000 Added 266.67%	11,000 $641,000
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $186,300 - $234,240	3,000 New	3,000 $190,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.